MG-LZ8™: Inside South Africa’s Most Rigorously Tested Reishi Extract

TRADE RESEARCH BRIEF

What the laboratory evidence means for your practice and your patients

Original review by Daleen Totten, Natural Medicine World (April 2026)  |  Summarised for wholesale trade reference

Reishi (Ganoderma lucidum) has more than two thousand years of use in Eastern medicine and a substantial body of modern pharmacological research behind it. The challenge for practitioners has never been the science — it has been sourcing a product that actually contains what it claims to. A 2017 independent audit of 19 commercially available reishi supplements found that only 5 matched their labels, with starch-based grain filler present in 68% of products tested.¹

 

MG-LZ8™, produced by Cape-based Mushroom Guru and sold as part of their GanodermaGOLD™ range, represents a genuinely different category. It is backed by five independent laboratories across eight years of documented testing — an evidence profile that is uncommon for any South African supplement product, and rare for a functional mushroom extract globally.

 

This brief summarises the key scientific findings for practitioners who want to understand the evidence before recommending or stocking the product.

The compound classes responsible for reishi’s documented effects are now well characterised: triterpenoids (primarily ganoderic acids) and immunomodulatory polysaccharides including beta-glucans. The evidence base spans several therapeutic areas:

 

• Immune & Organ Support: Immune modulation: regulatory rather than simply stimulatory, capable of both upregulating and calming immune activity depending on the state of the system¹¹
• Liver and kidney protection through antioxidant and cytoprotective mechanisms¹⁰
• Blood sugar stabilisation, cholesterol reduction and blood pressure regulation via HPA axis modulation
• Cognitive protection and neuroprotective potential, particularly relevant in age-related decline
• Stress resilience through natural cortisol regulation rather than forced adrenal stimulation

 

For practitioners, the key distinction is regulatory immune modulation — reishi polysaccharides have been shown to increase immune activity when it is suppressed and reduce inflammation when it is excessive, making this an adaptogenic immune intervention rather than a simple stimulant.

Three failure modes account for nearly all substandard reishi supplements in the market:

 

• Grain filler: Mycelium grown on grain substrate, then ground whole — producing a product high in starch and low in active compounds
• Incomplete extraction: Single-phase extraction (water only or ethanol only), capturing only one of the two distinct compound classes present in genuine reishi
• Spent biomass: Spent biomass: raw material from which active compounds have already been commercially extracted, dried, powdered and re-sold without disclosure

 

★	The 2017 Scientific Reports audit (Wu et al.) found authentic ganoderic acids in fewer than half of tested products, and primary immunoactive 1,3-β-D-glucan confirmed in only 5 of 19. South Africa uses the same global supply chains.

1. Antler Morphology: A Biochemically Superior Starting Material

Most commercial reishi is grown as a flat conk (bracket mushroom), distributing biological resources across a broad surface. Mushroom Guru cultivates a 35–40cm straight antler through controlled CO₂ and ventilation management — maintaining the organism in its most chemically productive growth phase before reproductive switching occurs.

 

A 2018 peer-reviewed study (Sudheer et al., Fungal Biology) confirmed that antler-type fruiting bodies contained approximately two-fold higher concentrations of phenolics, flavonoids, water-soluble polysaccharides and triterpenoid content compared to standard fruiting bodies.³

 

Independent HPLC analysis by Verve Dynamics (Somerset West, 2017) compared Mushroom Guru’s antler material against wild-harvested Knysna reishi and a commercially imported powder under identical conditions. Expert chromatographic interpretation indicated approximately a 12-fold triterpenoid concentration advantage for the antler material before any extraction had taken place.⁴

 

2. Dual-Phase Extraction: Capturing the Full Bioactive Spectrum

Reishi contains two pharmacologically active compound classes that cannot be co-extracted by any single method:

 

• Class 1: Fat-soluble ganoderic acids and triterpenoids require ethanol extraction
• Class 2: Water-soluble polysaccharides, beta-glucans and the LZ-8 immunomodulatory protein require hot water extraction

 

Mushroom Guru runs both phases sequentially and combines the outputs into a single finished extract, removing the chitin cell wall barrier in the process. The result: a complete-spectrum extract in a bioavailable form.

 

Process efficiency: 1kg of finished MG-LZ8™ is produced from 12kg of raw antler material. The internationally recognised NAMMEX benchmark standard requires 16kg of mushroom per 1kg of extract. Mushroom Guru captures more compound classes at a more efficient input ratio due to proprietary technique development refined over 13 years.⁴ʸ⁵

 

3. The 348× Concentration Cascade

★	12× antler triterpenoid advantage × 29× extraction concentration factor = 348× relative potency versus standard imported conk reishi powder. One 15mg capsule of MG-LZ8™ delivers the active compound equivalent of approximately 5,400mg of standard reishi powder.

 

Note on this figure: the 12× is based on expert HPLC chromatographic interpretation rather than formally quantified mass spectrometry comparison of antler versus wild conk. The 29× extraction factor is from Verve Dynamics’ HPLC analysis of total chromatographic area pre- and post-extraction under identical conditions.⁴

Species Verification

Inqaba Biotechnical Industries (Pretoria, 2025) conducted dual-marker molecular identification. ITS marker: 99.69% identity to Ganoderma sichuanense (synonym G. lingzhi, the pharmacopoeial reishi species). EF1-α marker: 100% identity. This is the definitive species authentication approach — morphology alone cannot reliably distinguish Ganoderma species.¹²

 

Mass Spectrometry: Compound Profile and Benchmark Comparison

Prof. Marietjie Stander at Stellenbosch University’s Central Analytical Facility (2021) conducted MS/QTOF mass spectrometry comparing MG-LZ8™ against:⁵

 

• A leading South African pharmaceutical competitor’s reishi product: MG-LZ8™ showed 11 identified triterpenoid compounds; the comparator showed little to no detectable triterpenoids, consistent with low-quality raw material or spent biomass.
• The NAMMEX international benchmark standard: MG-LZ8™ demonstrated 48.8% higher total integration value across all identified compounds, with one compound (GA/B) showing a 57-fold advantage for the antler extract.

 

This comparison establishes MG-LZ8™ as the analytical reference standard for antler-based reishi extraction, a distinct and measurably more concentrated category from traditional conk-based products.

 

Immunological Activity: University of Louisville Trial

In 2018, Mushroom Guru submitted MG-LZ8™ to Prof. Vaclav Větvicka at the University of Louisville (Kentucky), one of the world’s leading β-glucan and immune modulation researchers with over 250 peer-reviewed publications.⁹

 

• At the 100 µg dose, active neutrophils (cells responsible for phagocytosis of foreign material) rose from 31% baseline to 47% — a ~52% relative increase in phagocytic activity within 24 hours of a single dose
• IL-2 (a key T-cell activation signalling cytokine) rose more than 200-fold over baseline at the same dose
• No cytotoxic effects on cells were observed at any dose tested

 

★	Prof. Větvicka’s conclusion: “MG-LZ8™ is a biologically active sample with significant effects on immune reactions and showed no toxic effects on cells.”

 

Starch Testing: Grain-Free Confirmation

SANAS-accredited laboratory Mérieux NutriSciences (October 2023) tested MG-LZ8™ for starch content and found less than 0.50g per 100g — below the detection limit.⁶ Real reishi mushroom contains no starch. The 2017 audit found starch (grain filler) in 68.4% of tested products. This result confirms the absence of mycelium-on-grain biomass.

 

Heavy Metal Purity

Verve Dynamics heavy metal testing (October 2023) produced the following results against international limits:⁴

 

• Lead: 17× below international limit
• Cadmium: 55× below international limit
• Mercury: 50× below international limit
• Arsenic: undetectable

 

Consistent microbial compliance was also confirmed across batches tested three years apart. This is particularly relevant for practitioners working with immunocompromised patients or individuals with compromised detoxification capacity.

MG-LZ8™ contains five of the eight essential glyconutrients identified by Dr. Steve Nugent as required for immune cell communication: glucose, mannose, galactose, fucose and xylose. Most people obtain only two of these from their modern diet.

 

These sugars form complex polysaccharide structures that engage immune cell receptors (Dectin-1 and the mannose receptor CD206) directly on contact. The LZ-8 protein — the first mushroom immune protein ever discovered, unique to G. lucidum and absent in all other fungi — has a structure remarkably similar to human antibodies. Rather than forcing the immune system to work harder, LZ-8 restores natural communication pathways the body already recognises.

Research from the University of Pittsburgh has demonstrated that myeloperoxidase (MPO), an enzyme released by activated neutrophils, can catalytically break down carbon-based nanomaterials — a finding with potential relevance to oncology, where such materials are increasingly used as drug delivery vehicles.⁷ʸ⁸

 

Many chemotherapy protocols reduce neutrophil counts, and therefore MPO availability, potentially limiting the body’s ability to clear residual nanocarrier material post-treatment. MG-LZ8™’s demonstrated ability to increase neutrophil phagocytic activity by ~52% raises a theoretical question about whether β-glucan-mediated immunomodulation may support clearance and tissue protection pathways following oncology treatment.

 

★	Important: A clinical trial to investigate this has been proposed at Stellenbosch University and Tygerberg Academic Hospital but has not yet commenced. Any direct link between MG-LZ8™ and nanoparticle clearance remains theoretical pending that data.

Every product is built on the same MG-LZ8™ dual-phase extract. Dose and delivery format vary by application:

 

• 01 Immune Modulator Capsules: 15mg MG-LZ8™ per capsule, cassava root powder filler (grain-free). Daily systemic immune support. One capsule per day.
• 02 Targeted Therapy Drops: 2,400mg MG-LZ8™ per 30ml bottle via CHD-FA™ (Carbohydrate-Derived Fulvic Acid) + 3% pharmaceutical-grade DMSO. Sublingual absorption. 8 drops twice daily = 80mg/day. Clinical-intensity format for intensive immune support and post-treatment recovery.
• 03 Skin Serum: 24mg MG-LZ8™ per 30ml serum via 20% DMSO + 1% Namibian Myrrh. Transdermal delivery into lymphatic tissue. Primary applications: lymphatic support, rheumatoid arthritis, wound care and dermatological conditions.
• 04 Arnica Rub Gel: 40mg MG-LZ8™ + 150mg Arnica + 100mg CBD per 50ml jar via 7% DMSO. Three-mechanism pain and inflammation topical, developed with Canabliss. Applications: rheumatoid arthritis, muscle recovery, sprains and bruising.
• 05 Honey Snap Pack: 8mg MG-LZ8™ per 7g snap pack in Cape Eucalyptus honey (high propolis content). Single-serve format for daily maintenance or trial activation.
• 06 Pet Drops: 240mg MG-LZ8™ per 15ml bottle via CHD-FA™ + 3% pharmaceutical-grade DMSO. Alcohol-free. Weight-based dosing. For dogs and cats.

MG-LZ8™ is classified as a food supplement under South African law. However, its immune-modulating and blood-thinning properties create specific clinical considerations:

 

Do not use tincture or capsules with:

• Blood-thinning medication (warfarin, heparin, newer anticoagulants) — may increase bleeding risk
• Active autoimmune conditions on immunosuppressive therapy
• Post-organ-transplant anti-rejection medication
• Pregnancy or breastfeeding
• Known allergy to reishi mushrooms

 

Use with caution or delay commencement if:

• Severe liver impairment (liver enzymes above 3× normal)
• Severe renal impairment (kidney function below 30%)

 

No serious adverse events have been reported in commercial use to date.

• Species verified by dual-marker molecular ID (ITS 99.69%, EF1-α 100%) — the definitive method
• Antler morphology confirmed — a distinct and more bioactive growth form than commercial conk
• Dual-phase extraction captures both fat-soluble triterpenoids and water-soluble beta-glucans in one product
• 348× relative concentration versus standard imported reishi powder; 1 capsule = ~5,400mg equivalent
• 48.8% higher total compound integration than NAMMEX international benchmark in direct mass spectrometry comparison
• 52% increase in neutrophil phagocytic activity in University of Louisville independent trial (Prof. Větvicka)
• Zero cytotoxicity confirmed across two independent laboratory assessments
• Undetectable starch content (SANAS-accredited Mérieux NutriSciences) — no grain filler
• Heavy metals 17–55× below international limits; arsenic undetectable
• 32-year cultivation record; 8 years of multi-laboratory documented testing

The following peer-reviewed literature forms the primary evidence base referenced in this brief. Practitioners are encouraged to review the primary sources:

 

1. Wu DT et al. Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States. Scientific Reports. 2017;7:7792.

2. Chen S et al. Genome sequence of the model medicinal mushroom Ganoderma lucidum. Nature Communications. 2012;3:913.

3. Sudheer S et al. Development of antler-type fruiting bodies of Ganoderma lucidum and determination of its biochemical properties. Fungal Biology. 2018;122(5):293–301.

4. Davies RP. HPLC Certificate of Analysis — Reishi/Lingzhi mushroom extract, Ganoderma lucidum. Verve Dynamics (Pty) Ltd; July 2017. [Independent laboratory report]

5. Little T / Raluka Biotech. MS/QTOF Mass Spectrometry Comparative Report — MG-LZ8™ vs leading SA pharmaceutical comparator. Stellenbosch University Central Analytical Facility. 2021. [Independent laboratory report]

6. Mérieux NutriSciences. Certificate of Analysis N° 1803559-0. SANAS-accredited laboratory T0350. October 2023. [Independent laboratory report]

7. Kagan VE. Carbon Nanotube Biodegradation by Neutrophil Myeloperoxidase. NIH Final Progress Report, Grant R01 OH008282. University of Pittsburgh. October 2016.

8. Shvedova AA et al. Impaired clearance and enhanced pulmonary inflammatory/fibrotic response to carbon nanotubes in myeloperoxidase-deficient mice. PLoS One. 2012;7(3):e30923.

9. Větvicka V. Immunological Effects of MG-LZ8 Extract. Pre-clinical trial report. University of Louisville, Department of Pathology. September 2018. [Independent trial report]

10. Zhong D et al. Ganoderma lucidum polysaccharide peptide prevents renal ischaemia reperfusion injury via counteracting oxidative stress. Scientific Reports. 2015;5:16910.

11. Seweryn E et al. Health-Promoting Properties of Polysaccharides Extracted from Ganoderma lucidum. Nutrients. 2021;13(8):2725.

12. Inqaba Biotechnical Industries (Pty) Ltd. Molecular species identification report: Ganoderma sichuanense (synonym G. lingzhi). Dual-marker analysis. Report SA2025/195735. Pretoria: 2025. [Independent laboratory report]

13. Ondrejkovic G / Ecogreen Analytics. Certificate of Analysis, Lab ID JB25-029-01. February 2025. [Independent laboratory report]

Source: Original product review by Daleen Totten, Natural Medicine World, April 2026 — natmedworld.com/mg-lz8-south-africa-reishi-extract-review. Summarised for wholesale trade reference. This document does not constitute medical advice. Practitioners should review primary sources and apply clinical judgement.